India, Nov. 1 -- Every great tale has a beginning, but not every beginning offers a glimpse of the greatness that may lie ahead. Some journeys begin with an uncertain future only to unfold into extraordinary stories.
Merck & Co. Inc.'s (MRK) blockbuster drug Keytruda (Pembrolizumab) is one such story.
From 2023 through 2025, this immunotherapy drug maintained its top-seller status. But beyond its coveted Number 1 title, Keytruda has also made a meaningful difference in the lives of many cancer patients.
One name that is most often cited as an example of someone for whom the drug Keytruda played a role in remarkable recovery is former U.S. President Jimmy Carter. Carter was diagnosed with melanoma in his brain and liver in August 2015 and...